Optimal Use of Raltegravir (Isentress®) in the Treatment of HIV-Infected Adults – Canadian Consensus Guidelines
BACKGROUND AND OBJECTIVES: A meeting of a Canadian group with significant experience and knowledge in HIV management, consisting of five physicians, a pharmacist and an AIDS researcher, was convened. Their goal was to develop guidance for Canadian HIV-treating physicians on the appropriate use of ra...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2009-01-01
|
| Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
| Online Access: | http://dx.doi.org/10.1155/2009/940745 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560781592363008 |
|---|---|
| author | Anita Rachlis Jonathan B Angel Marianne Harris Stephen D Shafran Rachel Therrien Cécile Tremblay Mark A Wainberg |
| author_facet | Anita Rachlis Jonathan B Angel Marianne Harris Stephen D Shafran Rachel Therrien Cécile Tremblay Mark A Wainberg |
| author_sort | Anita Rachlis |
| collection | DOAJ |
| description | BACKGROUND AND OBJECTIVES: A meeting of a Canadian group with significant experience and knowledge in HIV management, consisting of five physicians, a pharmacist and an AIDS researcher, was convened. Their goal was to develop guidance for Canadian HIV-treating physicians on the appropriate use of raltegravir (MK-0518, Isentress®, Merck Frosst Canada Inc) in HIV-infected adults. |
| format | Article |
| id | doaj-art-0653f2f65e0b4f96aa6ea842cabf811d |
| institution | Kabale University |
| issn | 1712-9532 |
| language | English |
| publishDate | 2009-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Infectious Diseases and Medical Microbiology |
| spelling | doaj-art-0653f2f65e0b4f96aa6ea842cabf811d2025-02-03T01:26:41ZengWileyCanadian Journal of Infectious Diseases and Medical Microbiology1712-95322009-01-01203e67e8010.1155/2009/940745Optimal Use of Raltegravir (Isentress®) in the Treatment of HIV-Infected Adults – Canadian Consensus GuidelinesAnita Rachlis0Jonathan B Angel1Marianne Harris2Stephen D Shafran3Rachel Therrien4Cécile Tremblay5Mark A Wainberg6Division of Infectious Diseases, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, CanadaDivision of Infectious Diseases, Department of Medicine, Ottawa Hospital and University of Ottawa, Ottawa, Ontario, CanadaAIDS Research Program, St. Paul’s Hospital, Vancouver, British Columbia, CanadaDivision of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, CanadaCentre Hospitalier de l’Université de Montréal, CanadaDepartment of Microbiology and Immunology, Centre Hospitalier de l’Université de Montréal, CanadaMcGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montréal, Quebec, CanadaBACKGROUND AND OBJECTIVES: A meeting of a Canadian group with significant experience and knowledge in HIV management, consisting of five physicians, a pharmacist and an AIDS researcher, was convened. Their goal was to develop guidance for Canadian HIV-treating physicians on the appropriate use of raltegravir (MK-0518, Isentress®, Merck Frosst Canada Inc) in HIV-infected adults.http://dx.doi.org/10.1155/2009/940745 |
| spellingShingle | Anita Rachlis Jonathan B Angel Marianne Harris Stephen D Shafran Rachel Therrien Cécile Tremblay Mark A Wainberg Optimal Use of Raltegravir (Isentress®) in the Treatment of HIV-Infected Adults – Canadian Consensus Guidelines Canadian Journal of Infectious Diseases and Medical Microbiology |
| title | Optimal Use of Raltegravir (Isentress®) in the Treatment of HIV-Infected Adults – Canadian Consensus Guidelines |
| title_full | Optimal Use of Raltegravir (Isentress®) in the Treatment of HIV-Infected Adults – Canadian Consensus Guidelines |
| title_fullStr | Optimal Use of Raltegravir (Isentress®) in the Treatment of HIV-Infected Adults – Canadian Consensus Guidelines |
| title_full_unstemmed | Optimal Use of Raltegravir (Isentress®) in the Treatment of HIV-Infected Adults – Canadian Consensus Guidelines |
| title_short | Optimal Use of Raltegravir (Isentress®) in the Treatment of HIV-Infected Adults – Canadian Consensus Guidelines |
| title_sort | optimal use of raltegravir isentress r in the treatment of hiv infected adults canadian consensus guidelines |
| url | http://dx.doi.org/10.1155/2009/940745 |
| work_keys_str_mv | AT anitarachlis optimaluseofraltegravirisentressinthetreatmentofhivinfectedadultscanadianconsensusguidelines AT jonathanbangel optimaluseofraltegravirisentressinthetreatmentofhivinfectedadultscanadianconsensusguidelines AT marianneharris optimaluseofraltegravirisentressinthetreatmentofhivinfectedadultscanadianconsensusguidelines AT stephendshafran optimaluseofraltegravirisentressinthetreatmentofhivinfectedadultscanadianconsensusguidelines AT racheltherrien optimaluseofraltegravirisentressinthetreatmentofhivinfectedadultscanadianconsensusguidelines AT ceciletremblay optimaluseofraltegravirisentressinthetreatmentofhivinfectedadultscanadianconsensusguidelines AT markawainberg optimaluseofraltegravirisentressinthetreatmentofhivinfectedadultscanadianconsensusguidelines |